Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2022 earnings results today. Reported sales decreased 4.4% year-over-year to $23.7 billion. Net earnings were down 25% to $3.5 billion, or $1.33 per share, compared to the prior-year period. Adjusted EPS increased 10.3% to $2.35 from last year. Adjusted EPS beat estimates while sales fell short […]
“Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2022 earnings results today. Reported sales decreased 4.4% year-over-year to $23.7 billion. Net earnings were down 25% to $3.5 billion, or $1.33 per share, compared to the prior-year period. Adjusted EPS increased 10.3% to $2.35 from last year. Adjusted EPS beat estimates while sales fell short […]
· January 24, 2023
Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2022 earnings results today.
Reported sales decreased 4.4% year-over-year to $23.7 billion.
Net earnings were down 25% to $3.5 billion, or $1.33 per share, compared to the prior-year period. Adjusted EPS increased 10.3% to $2.35 from last year.
Adjusted EPS beat estimates while sales fell short of expectations.
For the full year of 2023, the company expects reported sales to range between $96.9-97.9 billion and adjusted EPS to range between $10.45-10.65.
